-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyoto iCAP fund makes USD 600,000 follow-on investment in Kanjin Therapeutics

PUBT·07/31/2026 01:19:45
Listen to the news
Kyoto iCAP fund makes USD 600,000 follow-on investment in Kanjin Therapeutics
  • Kyoto University Innovation Capital made a USD 600,000 follow-on investment in Kanjin Therapeutics via its Innovation Kyoto 2021 fund.
  • Kanjin develops drug candidates for chronic kidney disease, based on research from Okayama University professor Masataka Nakayama.
  • Proceeds target nonclinical studies, formulation development, R&D expansion, preparation for regulatory clearance to start clinical trials.
  • Kanjin is headquartered in Fremont, California, operating a Japan-US cross-border development model.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyoto University Innovation Capital Co Ltd published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.